Absolute quantification of graft-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation – results from a prospective observational trial (Oellerich et al. AACC 2018)

Download PDF

By | August 28th, 2018|Medical publications, Transplant|0 Comments

Schütz E et al. Graft-derived cell-free DNA – a promising rejection marker in cardiac transplantation – Results from a prospective observational trial. 69th AACC Annual Scientific Meeting Abstract eBook (2017):A-121

Download PDF

By | August 28th, 2018|Medical publications, Transplant|0 Comments

Schütz E et al. Graft-derived cell-free DNA a promising Rejection Marker in Liver transplantation Results from a prospective Multicenter Trial. Clin Chem (2016): suppl. A121

Download PDF

By | August 28th, 2018|Medical publications, Transplant|0 Comments

Beck J et al. A new universal multiplex digital PCR method with improved precision for the quantification of donor derived graft DNA traces Clin Chem (2015): suppl

Download PDF

By | August 28th, 2018|Medical publications, Transplant|0 Comments

Beck J et al. Early Detection of Rejection after Heart Transplantation by a universal digital PCR method Clin Chem (2015): suppl

Download PDF

By | August 28th, 2018|Medical publications, Transplant|0 Comments

Beck J et al. Use Of Plasma GcfDNAQuantification To Guide Personalized Immunosuppression. Transplant International 27 (2014): 50

Download PDF

By | August 28th, 2018|Medical publications, Transplant|0 Comments

Beck J et al. Absolute Quantification of Graft derived cell-free DNA (GcfDNA) early after Liver Transplantation (LTx) using droplet Digital PCR. Clin Chem 2015: suppl

Download PDF

By | August 28th, 2018|Medical publications, Transplant|0 Comments

Chronix Biomedical reports positive interim pancreatic cancer data

Chronix Biomedical reports a positive interim analysis of its ongoing validation study of its Copy Number Instability (CNI)-based therapeutic monitoring test in pancreatic cancer. The study compares the accuracy of Chronix’s CNI-based test at predicting a clinical response, as early as after the first cycle of chemotherapy compared to CA19-9, a commonly used biomarker.

By | June 14th, 2017|Chronix news|0 Comments

Chronix Biomedical is pleased to be a sponsor of the PCRT annual meeting

Chronix Biomedical

Chronix looks forward to working with this team of international pancreatic cancer experts.

By | June 2nd, 2017|Chronix news|0 Comments

Chronix at the ASCO 2017 Annual Meeting

Chronix Biomedical

This is the third year that Chronix is presenting its study results at ASCO — this year’s results are from a blinded prospective study validating the use of a CNI Monitor blood test to predict the treatment outcome of patients undergoing immunotherapy.

By | June 2nd, 2017|Chronix news|0 Comments